CD274 and neoplasm: The IMpower 110, a phase 3 randomized clinical trial (RCT), compared first-line therapy with single-agent atezolizumab versus platinum-based chemotherapy (CT) in patients with untreated PD-L1 ≥ 1% (on tumor cells or tumor-infiltrating immune cells as assessed by the SP142 IHC assay) mNSCLC.